TRANSCRIPT

Q1 2024 — Prepared remarks

Q1 2024PDF · 13 pages256 KB
1
Philip Morris International Inc.
2024 First-Quarter Conference Call
April 23, 2024
JAMES BUSHNELL
(SLIDE 1.)
Welcome. Thank you for joining us. Earlier today, we issued a press release containing
detailed information on our 2024 first-quarter results. The press release is available
on our website at www.pmi.com.
(SLIDE 2.)
A glossary of terms, including the definition for smoke-free products as well as
adjustments, other calculations and reconciliations to the most directly comparable
U.S. GAAP measures for non-GAAP financial measures cited in this presentation are
available in Exhibit 99.2 to the company's Form 8-K dated April 23, 2024, and on our
Investor Relations website.
(SLIDE 3.)
Today’s remarks contain forward-looking statements and projections of future results.
I direct your attention to the Forward-Looking and Cautionary Statements disclosure
in today’s presentation and press release for a review of the various factors that could
cause actual results to differ materially from projections or forward-looking statements.
I’m joined today by Emmanuel Babeau, Chief Financial Officer, and Jennifer Motles,
Chief Sustainability Officer.
Over to you, Emmanuel.

-- 1 of 13 --

2
EMMANUEL BABEAU
(SLIDE 4.)
Thank you, James, and welcome everyone.
In Q1, we delivered outstanding performance that exceeded our expectations, with
double-digit growth in organic net revenue and operating income, as well as currency-
neutral adjusted diluted EPS, all supported by robust volume growth. Excellent smoke-
free business momentum continues with 25% organic growth in net revenues and 38%
in gross profit, as IQOS operating leverage and ZYN mix contribute positively.
IQOS continues to advance rapidly, with growth of 13% in adjusted IMS volumes and
21% in shipments. IQOS ILUMA is a key driver of this progress and is now available
in 64 markets, representing nearly 100% of IQOS volumes outside Russia. ZYN also
continued its considerable growth in Q1, with U.S. volumes up 80%.
Importantly, this top-line performance translated into strong OI growth and margin
expansion, both organically and in dollar terms. This was notably driven by
accelerating profitability in both our IQOS and ZYN businesses, in addition to
improving combustible performance.
We faced higher-than-expected currency headwinds in the quarter, primarily due to
the devaluation of the Egyptian pound. We are taking mitigating actions including
additional pricing and accelerated cost initiatives, which allowed us to deliver Q1
adjusted diluted EPS above our prior expectation, despite these pressures.
While the prior year quarter was favorable for certain growth comparisons, this
exceptional start to the year sets the stage for us to deliver significantly better-than-
expected 2024 currency-neutral growth, and robust growth in USD at prevailing rates.
(SLIDE 5.)
Turning to the headline numbers, very good shipment volume growth of 3.6%
supported organic top-line growth of 11.0%, or 8.6% including currency. This reflects
continued excellent IQOS and ZYN momentum as well as strong combustible pricing.
Operating income grew by 22.2% organically versus a softer prior-year quarter,
notably driven by gross margin expansion and a deceleration in SG&A growth. As a
result, our organic OI margins expanded by 3.7 percentage points. In dollar terms,
adjusted OI grew by 11.3% and adjusted OI margins expanded by 0.9pp.

-- 2 of 13 --

3
We outperformed our Q1 adjusted EPS outlook due to three main factors. The first is
the net revenue and profit impact of better volumes following the industry-leading
performance of ZYN, the strong shipment growth of IQOS HTUs including some
higher-than-expected timing benefits, and a resilient combustible delivery. Second is
the benefit of our pricing actions to mitigate currency headwinds and third is on cost
including some timing benefit and a stepped-up focus on manufacturing and back-
office efficiencies to prioritize growth investments. The majority of the outperformance
was driven by underlying business dynamics, which bodes well for the remainder of
the year.
Indeed, we delivered adjusted diluted EPS of $1.50, representing 23.2% growth
excluding an unfavorable currency impact of 20 cents. This includes 9 cents from the
devaluation of the Egyptian pound, including a transactional impact of 6 cents primarily
related to the balance sheet remeasurement of foreign currency payables. With
increased liquidity in the EGP, we are now reducing our balance sheet exposure, and
this should be complete in the coming weeks.
(SLIDE 6.)
Focusing now on volumes, our Q1 HTU shipments of 33.1 billion units exceeded our
outlook, with robust underlying growth across geographies and a higher-than-
anticipated timing impact of shipments to Japan. The incremental phasing impact was
around 1 billion units and was primarily related to Red Sea disruption. While uncertain,
we assume this will normalize in the second half of the year.
As mentioned previously, we believe the best indicator of underlying HTU growth is
adjusted IMS, as the closest metric to consumer offtake. Adjusted IMS volume grew
nicely by 12.5%, including the expected impact from the characterizing flavor ban in
Europe. We continue to see strong IQOS momentum, with excellent growth in Japan,
robust underlying fundamentals in Europe, and a growing contribution from newer
markets such as Indonesia. We continue to target 14-16% adjusted IMS growth for the
year, with around 10% growth in Q2 followed by an H2 acceleration driven by the
timing of commercial programs, ILUMA uptake, newer markets and a less demanding
prior year comparison.
Total smoke-free volume growth of 22% includes the impressive expansion of our oral
smoke-free portfolio powered by ZYN, with pouch equivalent shipment volumes up by
35.8%. U.S. ZYN shipments grew by 80% to 132 million cans.
Cigarette shipments declined by a modest 0.4% in the first quarter, with a notable
positive contribution from Turkey as we increased share in a strong overall market.

-- 3 of 13 --

4
(SLIDE 7.)
Let me now walk through the drivers of our Q1 net revenues. As I mentioned, volumes
grew by a remarkable 3.6%, including oral. Pricing contributed 5.5 points of growth
primarily from combustibles, as well as pricing of around 3% on HTUs.
Smoke-free category mix added 3.1 percentage points to the top-line, reflecting the
higher net revenue per unit of IQOS and, to an even greater extent, ZYN. Oral SFP
overall boosted our organic net revenue growth by 2.2 points, showcasing its role as
a meaningful accelerator. I am also pleased to report a positive contribution from our
VEEV e-vapor business which, while still small in the context of the group, delivered
good revenue growth.
As in 2023, there was a negative geographic mix within our combustible business as
lower margin markets, often without smoke-free products, grew faster; and smoke-
free products accelerated cigarette declines elsewhere.
The positive category mix impact of smoke-free products, overall volume growth, and
pricing are the three enduring engines of our transformation and growth.
(SLIDE 8.)
Focusing now on the key dynamics of our Q1 profit delivery, smoke-free gross profit
grew by an impressive 38% organically, on top-line growth of 25%. This reflects the
very strong performance of U.S. ZYN and the growth and scale effects of IQOS,
including manufacturing productivities. This strong underlying acceleration was
amplified by only a few percentage points due to HTU shipment phasing. Gross
margins expanded substantially for both heat-not-burn and oral nicotine, and by a
striking 600 basis points organically for smoke-free overall, which made up close to
39% of total gross profit, an increase of 6 percentage points versus prior year.
Combustible organic gross profit growth was notably improved and exceeded our
expectation at 2.3%. Gross margins were also better-than-anticipated, leading to an
improved full year outlook. Resilient volumes, strong pricing and manufacturing
productivities more than offset the continued cost pressures in the category,
geographic mix, and the impact of IQOS cannibalization. As previously flagged, cost
increases in leaf, wages and certain other inputs carried over into 2024, and these
should ease next year. We were also impacted by around $30 million of costs from
implementation of the EU Single-Use Plastics Directive, primarily on cigarettes.

-- 4 of 13 --

5
(SLIDE 9.)
A key feature of Q1 was strong OI margin expansion. Gross margins increased
organically by 150 basis points and by 80 basis points including currency. This reflects
excellent expansion within smoke-free products, their growing weight within our
business at higher margins, and the better-than-expected evolution of combustibles.
These factors, combined with productivity savings, significantly outweighed the
unfavorable technical dilutive impact of third-party manufacturing in Indonesia, which
equated to 30 basis points in the quarter.
For SG&A costs, currency-neutral growth of only 1.4% drove 220 basis points of
organic margin expansion. This benefitted from our resource allocation and
prioritization programs, including the delivery of approximately $160 million in gross
cost efficiencies across COGS and SG&A towards our $2 billion target for 2024-26.
Although the Q1 margin impact of SG&A cost evolution including currency was small
due notably to Egyptian Pound transactional currency, we continue to target SG&A
progression below top-line growth for the year. We expect higher organic SG&A
increases in the remainder of 2024, notably reflecting investment spend phasing,
which was favorable in Q1.
The combination of these factors powered a remarkable 370 basis point expansion in
our organic OI margins, and 90 basis points including currency. This exceeded our
expectations and we are now raising our full-year OI growth outlook, as I will come
back to.
(SLIDE 10.)
Taking another lens on adjusted OI margins by geography, we see broad-based global
momentum with all regions delivering strong organic progress. In dollar terms, margins
expanded in every region except the SSEA, CIS, and MEA region, mainly reflecting
the transactional currency impact of the Egyptian pound and the technical dilution in
Indonesia. Indeed, excluding these factors, this region grew margins at a very similar
rate to the group.
(SLIDE 11.)
Moving to IQOS. With ILUMA now widely launched, PMI HTUs continue to strengthen
their position as the second largest nicotine 'brand' in markets where IQOS is present.
PMI HTUs now exceed the 10% market share milestone on the prior basis excluding
Indonesia, which we now include following broader commercialization in the market.
Our HTUs are the #1 nicotine ‘brand’ in 11 markets, and as shown at CAGNY, IQOS
net revenues have surpassed those of Marlboro.

-- 5 of 13 --

6
(SLIDE 12.)
Focusing on IQOS in Europe, Q1 HTU share increased by 0.9 points, also crossing
the 10% regional share milestone for the first time. While still early in many markets,
the growing availability and uptake of ILUMA is a key driver and we are seeing a strong
acceleration in a number of historically slower-growth markets.
Adjusted IMS volumes continue to exhibit robust sequential growth and reached a
record high of 12.6 billion units on a four-quarter moving average. This reflects year-
on-year progression of 9.4% in Q1, with excellent growth in Greece, Portugal,
Germany, Spain, UK and the Netherlands. Growth was slower in certain Central
European markets such as Poland and Czech Republic, where increased economic
pressures and price-sensitivity are visible. We continue to evolve our portfolio in these
markets under the recently-launched ILUMA system to drive further growth. Excluding
Ukraine, where growth was absent, adjusted IMS grew double-digit.
As anticipated, the 11 markets so far affected by EU characterizing flavor restrictions
saw an impact in line with our total region estimate of around 2 billion sticks for the
year. Consistent with similar past situations, we observe an initial consumer
adjustment followed by a reversion of growth rates to previous levels. We have not
seen meaningful shifts towards e-vapor or competitor heat-not-burn products, and we
expect the structural growth of IQOS to fuel continued HTU progression over the rest
of the year.
(SLIDE 13.)
The strong fundamental progress in the region is highlighted by the expansion in key
city offtake shares. Very strong gains in cities with already high IQOS adoption, such
as Lisbon, Rome, Athens and Budapest, demonstrate the potential for further growth
at the national level. The recent acceleration in London, Madrid, Munich and
Amsterdam is also very promising for the IQOS brand in these markets and for Europe
overall.
(SLIDE 14.)
In Japan, the adjusted total tobacco share for our HTU brands increased by an
excellent 3.1 points to 29.3%. Adjusted IMS volumes increased by 13%, maintaining
the rapid progress of recent quarters. Such impressive growth in a market with
already-high category penetration is a clear testament to the sustainable growth
potential of IQOS around the world.

-- 6 of 13 --

7
In connection with IQOS’ strong brand equity and commercial footprint, we are
fostering growth through continued innovation on both devices and consumables. In
March, we launched the latest IQOS device ILUMA i in direct channels, with national
expansion ongoing.
(SLIDE 15.)
We remain laser focused on innovation. Our innovation in consumables has included
a number of new variants and taste experiences on the premium TEREA brand. As
shown by the offtake data on this chart, this has helped TEREA to continue growing
Japan share at the same time as mainstream-priced SENTIA. This successful strategy
of broadening consumer appeal with different price tiers while reinforcing and growing
the premium line-up is a good illustration of how our IQOS business is evolving across
markets as the category continues to grow.
The potential of the category is clearly demonstrated by the performance in Tokyo. As
shared at CAGNY, heat-not-burn category volumes surpassed combustibles in
January and have continued to grow since then.
Led by Japan and Korea, the East Asia & Australia region reached almost two-thirds
smoke-free net revenues in Q1. While somewhat flattered by shipment timing, this
clearly demonstrates the path forward for the broader company as we strive towards
our ambition of becoming substantially smoke-free, surpassing two-thirds by 2030.
(SLIDE 16.)
Outside of Japan and Europe, we continue to see very promising IQOS growth across
the globe, including low and middle-income markets, as highlighted by key city offtake
shares.
A notable call-out is Indonesia, where we have expanded commercialization to
targeted areas in new cities and introduced TEREA clove variants catering to kretek
taste preferences. We have witnessed an uplift in user growth, and now have over
150,000 estimated IQOS users in the country. Our city offtake share in Urban Jakarta
is one indicator of this, with 1.6pp growth to 3.4% in a growing total industry.
We are also pleased to report the reacceleration of IQOS growth in South Korea
following the introduction of ILUMA. TEREA recently became the number one HTU
brand as measured by national c-store offtake, and in Seoul IQOS market share grew
by 1.8 points to 12.8%.

-- 7 of 13 --

8
Egypt continues to stand out with Cairo offtake share up 1.3 points to 9.1% despite
recent pricing, and we also see promising results in Malaysia, Morocco, Lebanon and
the Balkans. While not shown on this slide, Saudi Arabia also had a promising restart
with Q1 national offtake share of 1.3% following the resumption of IQOS
commercialization in late 2023.
In a similar vein to some of our European markets, the November launch of ILUMA in
Canada has coincided with an acceleration in key city growth, as shown here by
Toronto. While still early days for ILUMA and in a very restrictive regulatory
environment, this is clearly a positive development.
(SLIDE 17.)
Moving now to ZYN, where excellent U.S progress continued in Q1 with 70%
sequential growth in 12-month rolling shipments.
Impressively, category volume share grew for the fourth consecutive quarter to 74.3%,
an increase of 6.9 points year-on-year and 1.3 points sequentially despite a 15 cent
per can price increase in March. Retail value share also grew to 79.3%, highlighting
ZYN’s premium positioning and superior brand equity.
This accelerated growth again reflects a broad step-up in nationwide store velocities
and gradual distribution expansion as the category gains strong traction with adult
nicotine users.
As outlined at CAGNY, we remain focused on marketing ZYN responsibly to prevent
unintended use. We support the FDA's efforts to ensure only consumers over 21 have
access to nicotine products. Swedish Match follows a robust U.S. marketing code that
prohibits using social media influencers, age-gates digital platforms to 21-plus and
includes partnering with WeCard to help ensure retail sales only to legal-age adults.
(SLIDE 18.)
I’d like to spend a moment now on combustibles, where our portfolio delivered robust
organic net revenue growth of 3.7% in Q1. This primarily reflects better-than-expected
pricing of 7.9%, with a notable contribution from Germany, and stepped-up pricing in
Egypt. The pricing environment remains favorable, and we now forecast a full-year
increase of 6% to 7%, with annualization effects lessening in H2.
Our cigarette category share grew by 0.3 points in Q1. This includes positive
contributions from Algeria, Poland, and Turkey, resulting in only a modest volume
decline in a total cigarette industry which fell by 0.6%. Our global brands gained

-- 8 of 13 --

9
category share during the quarter, with Marlboro gaining 0.4 points. As previously
flagged, our 2023 share of segment was flattered by competitor supply constraints in
Egypt which may normalize this year.
As I already mentioned, strong pricing in Q1 coupled with accelerated manufacturing
productivities also resulted in a better-than-expected margin evolution.
(SLIDE 19.)
Now, let me provide an update on our latest innovation and expansion plans as we
further accelerate our smoke-free transformation.
As I covered earlier, we recently launched IQOS ILUMA i, our most innovative offering
to-date, in Japan. The ILUMA i portfolio consists of three devices offering a range of
adaptable new features. This includes the new touch screen on the device’s holder
which allows users to see experience-relevant information quickly and easily, as well
as a pause mode so users can pause and resume their smoke-free moment where
they left off. Initial consumer feedback has been very positive. Japan was the first
market to launch ILUMA in H2, 2021 and we plan to gradually roll-out ILUMA i to more
geographies over time.
As shown in our Japan and Indonesia performance, consumable innovation on the
ILUMA platform is also critical, as we broaden offerings across markets. LEVIA HTUs,
which contain nicotine but no tobacco leaf, were launched nationwide in the Czech
Republic and Romania in Q1 with promising initial results. More markets are planned
later this year. DELIA, our new mainstream-price brand for HTUs, was rolled out in
Switzerland, Hungary, and Lithuania.
In the U.S., we continue to prepare for the first consumer pilots in select cities with the
IQOS 3 system. As mentioned previously, the commercialization will be initially limited
in scope and will be focused on direct activation of select legal-age nicotine users in a
few cities, allowing us to experiment with different elements of the commercial model.
The main purpose of these consumer activations is to fine-tune our approach in
anticipation of the at-scale launch of IQOS ILUMA, following authorization from the
FDA.
The international expansion of nicotine pouches remains a key focus, notably for ZYN
as the world’s leading brand. We have launched or relaunched in 11 markets so far,
with more planned later this year.

-- 9 of 13 --

10
In e-vapor, our focused strategy for VEEV is showing very good early results. Positive
consumer feedback is translating into promising repeat-purchase and conversion
rates, and we are on a path to profitability in H2.
(SLIDE 20.)
This brings me to our outlook for 2024. With unparalleled smoke-free volume
momentum, best-in-class pricing and expanding margins we are raising our full year
currency-neutral growth forecasts. This strong pricing, combined with positive smoke-
free mix and efficient cost allocation also helps us to mitigate currency headwinds and
should allow us, at prevailing rates, to deliver on our objective of robust growth in dollar
terms.
Given continued ZYN volume progress, we are increasing our U.S. shipment forecast
to around 560 million cans. We have further accelerated our capacity expansion plans
to support this additional step-up. We continue to target strong growth in both adjusted
IMS and shipments of IQOS HTUs, and to reach close to $15 billion in 2024 smoke-
free net revenues at prevailing exchange rates.
Factoring the increased ZYN shipment forecast and a strong pricing outlook on both
combustibles and smoke-free products, we are increasing our organic net revenue
growth forecast to 7% to 8.5%.
In addition to higher revenue growth, we expect accelerated organic margin
expansion. This is strongly driven by a significant expected uplift in our smoke-free
gross margin due to IQOS scale effects, ZYN mix and accelerated manufacturing
productivities. It also includes organic gross margin expansion in combustibles, where
we had previously assumed a negative development. In addition, we are focused on
delivering further SG&A efficiencies while continuing to invest in smoke-free growth.
As a result, we are raising our organic OI growth forecast to 10% to 12%.
Accordingly, we are raising our forecast currency-neutral adjusted diluted EPS growth
to 9% to 11%. This translates into an adjusted diluted EPS range of $6.19 to $6.31,
including an unfavorable currency impact of 36 cents, at prevailing rates. The
increased forecast headwind is primarily explained by the devaluation of the Egyptian
pound and recent weakness in the Japanese Yen. As I mentioned, we are taking pro-
active actions to mitigate the incremental impact.
We expect full-year gross and OI margin expansion, in both organic and dollar terms,
at prevailing exchange rates. This includes organic expansion in both H1 and H2. After
the excellent Q1 performance, we expect a strong H1 overall with organic net revenue
and OI growth around the high end of our full year ranges.

-- 10 of 13 --

11
For Q2 specifically, we assume HTU shipment volumes of 34 to 35 billion and
continued strong volume growth from ZYN. We forecast currency-neutral adjusted
diluted EPS of $1.50 to $1.55, including an unfavorable currency variance of 14 cents,
at prevailing rates.
With regard to our balance sheet, deleveraging remains a key priority. We continue to
target a 0.3-0.5x improvement in our net debt to adjusted EBITDA ratio in 2024, driven
by profit growth and strong cash flow generation. We also continue to target reaching
around 2x by the end of 2026 and will consider buybacks once confirmed we are on-
track.
Now switching gear. As this quarter coincides with the publication of our 2023
Integrated Report, I would like to welcome Jennifer Motles, PMI Chief Sustainability
Officer, to share an update on our sustainability progress. Jennifer, over to you.
JENNIFER MOTLES
(SLIDE 21.)
Thank you, Emmanuel. I am very pleased to be joining today’s earnings call.
As Emmanuel mentioned, our sustainability, transformation, and business strategies
are one and the same. We are focused on creating value for the long-term, where
generating shareholder returns requires us to deliver on transformation, and delivering
on transformation requires us to deliver on sustainability. As shown in our recent
results, our product transformation fosters profitable growth and short-, medium-, and
long-term value creation. However, our transformation also means reshaping both our
value chain and how we engage with society. As we venture into new product
categories, we actively collaborate with different stakeholders and advocate for
regulatory frameworks that can accelerate industry change and end smoking.
Business transformation is a company-specific journey, which sustainability reporting
standards and frameworks often fail to adequately capture. To help illustrate our
progress toward achieving our smoke-free purpose, we regularly report our Business
Transformation Metrics, a bespoke set of financial and non-financial KPIs. Some of
them were already presented by Emmanuel in our financial results; others you can
see here. For example, the growing proportion of commercial and R&D spend on
smoke-free products demonstrates the allocation of resources away from our legacy
business and towards replacing cigarettes with better alternatives.

-- 11 of 13 --

12
As another example, increasing the availability and access of adult smokers around
the world to smoke-free products are two key pillars of achieving this replacement. As
our geographic expansion continues, low- and middle-Income markets now make up
47% of our market presence.
(SLIDE 22.)
These metrics, together with our overall performance for 2023, can be found in our
latest Integrated Report, published last month and available on our website. It is a
comprehensive document covering our most important sustainability topics, starting
with our product.
The report highlights progress on our continued expansion of smoke-free alternatives
across categories and geographies, as well as social and environmental programs
deployed with and in parallel to these products in support of sustainable value creation.
These include responsible marketing and sales practices, youth access prevention
programs, and efforts to reduce post-consumer waste. Further, it highlights our
progress on improving the quality of life of people in our supply chain, decarbonizing
our operations and value chain, and preserving nature.
We are also very pleased with the continued recognition of our sustainability
performance and robust reporting. To highlight just a few from 2023, PMI was included
in the Dow Jones Sustainability World Index for the first time, and for the fourth year
in DJSI North America. In addition, PMI was the only U.S. company to obtain a “Triple
A” rating from CDP. More than 20,000 companies worldwide participated in this rating,
and only 10 obtained this prestigious recognition.
Notably for investors in parts of Europe, but also in ESG or sustainability-themed funds
in the U.S., we are subject to sector exclusion policies because we are a Tobacco
company. It is clear that excluding companies or sectors from the consideration set
does nothing to address the underlying reasons for the exclusion, which in our case
would be the harm linked to combustible tobacco use. Many funds that may be
excluding tobacco on ESG considerations will still own stocks in other consumer
sectors, despite many of these companies not having comparable harm reduction
strategies in place to address the impacts of their products. As we transform our
company away from combustibles and work to end smoking at a societal level, we
welcome the engagement and challenge of investors to help us accelerate this critical
shift.
Thank you. I'll now turn it back to Emmanuel.

-- 12 of 13 --

13
EMMANUEL BABEAU
(SLIDE 23.)
Thank you, Jennifer. I will conclude today’s presentation with some key messages.
Our excellent IQOS and ZYN volume momentum, best-in-class pricing, positive
category mix and stepped-up cost efficiencies put us on track for a strong 2024, with
accelerated top-line growth and margin expansion.
Following an exceptional and better-than-expected start to the year, we have raised
our full year currency-neutral growth forecasts. Critically, we are also focused on
delivering performance in dollars. We are taking measures to mitigate currency
headwinds through pricing, accelerated manufacturing productivities and judicious
resource allocation to prioritize growth investments.
Our 2024 outlook places us firmly on track to deliver our 2024-26 CAGR targets.
Beyond 2026, we have further exciting opportunities to grow our smoke-free business
as we progress towards our ambition of being substantially smoke-free by 2030.
Finally and importantly, our strong growth outlook and highly cash generative business
underpins our ability to deleverage while maintaining a steadfast commitment to our
progressive dividend policy. We look forward to further rewarding our shareholders as
our transformation delivers sustainable growth.
(SLIDE 24.)
Thank you. We are now happy to answer your questions.
JAMES BUSHNELL
(SLIDE 25.)
That concludes our call today. Thank you for joining us. If you have any follow-up
questions, please contact the Investor Relations team. Thank you again and have a
nice day.

-- 13 of 13 --